MedTrace Logo

Clinical Evaluation of Flortaucipir F 18

NCT02278367 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 179

Last updated 2020-09-10

Study results available
· View outcomes & findings →

Summary

This study is designed to expand the database of flortaucipir F 18 safety and tau binding as measured by PET imaging and to provide standardized conditions for flortaucipir PET use, data collection and analysis to facilitate companion studies including, but not limited to, longitudinal studies of aging, depression, and traumatic brain injury.

Conditions

Interventions

DRUG

Flortaucipir F18

IV injection, 370 MBq (10 mCi), up to two doses

PROCEDURE

Brain PET scan

positron emission tomography (PET) scan of the brain

Sponsors & Collaborators

  • Avid Radiopharmaceuticals

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-12-31
Primary Completion
2019-06-26
Completion
2019-06-26
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02278367 on ClinicalTrials.gov